The Americas Cancer Immunotherapy Market continues to benefit from advancements in targeted therapy approaches, with MRFR reporting that the market will grow from USD 100.54 billion in 2024 to USD 118.27 billion by 2032, at a CAGR of 15.32%. Targeted therapies are designed to attack specific cancer cells without harming surrounding healthy tissues, making them a preferred option in precision oncology. This segment has gained traction due to the increased understanding of genetic and molecular cancer mechanisms, which enables the development of drugs that can block cancer growth signals more effectively. North America leads the adoption curve, thanks to extensive R&D investments, advanced diagnostic capabilities, and high awareness among oncologists. Latin America, while growing at a slower pace, is also witnessing rising uptake due to improving healthcare infrastructure and expanding access to innovative treatments. Key trends include the integration of targeted therapies with checkpoint inhibitors and personalized immunotherapy solutions, both of which are shaping the competitive landscape across the Americas.